244 related articles for article (PubMed ID: 35681277)
1. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer.
Han S; Shi T; Liao Y; Chen D; Yang F; Wang M; Ma J; Li H; Xu Y; Zhu T; Chen W; Wang G; Han Y; Xu C; Wang W; Cai S; Zhang X; Xing N
J Transl Med; 2023 Mar; 21(1):194. PubMed ID: 36918939
[TBL] [Abstract][Full Text] [Related]
3. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
5. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
[No Abstract] [Full Text] [Related]
6. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
7. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
8. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
9. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
10. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
11. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
12. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration.
Long X; Hou H; Wang X; Liu S; Diao T; Lai S; Hu M; Zhang S; Liu M; Zhang H
Cell Death Dis; 2020 Sep; 11(9):779. PubMed ID: 32951005
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer.
Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C
Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
Kim M; Song C; Jeong IG; Choi SK; Park M; Shim M; Kim YS; You D; Hong JH; Kim CS; Ahn H
BMC Cancer; 2018 Mar; 18(1):271. PubMed ID: 29523103
[TBL] [Abstract][Full Text] [Related]
17. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer.
Lv D; Cao Z; Li W; Zheng H; Wu X; Liu Y; Gu D; Zeng G
Front Surg; 2021; 8():665115. PubMed ID: 34136527
[No Abstract] [Full Text] [Related]
19. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]